Your browser doesn't support javascript.
loading
Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours.
Konstantinopoulos, Panagiotis A; Cheng, Su-Chun; Supko, Jeffrey G; Polak, Madeline; Wahner-Hendrickson, Andrea E; Ivy, S Percy; Bowes, Brittany; Sawyer, Hannah; Basada, Patrice; Hayes, Martin; Curtis, Jennifer; Horowitz, Neil; Wright, Alexi A; Campos, Susana M; Ivanova, Elena V; Paweletz, Cloud P; Palakurthi, Sangeetha; Liu, Joyce F; D'Andrea, Alan D; Gokhale, Prafulla C; Chowdhury, Dipanjan; Matulonis, Ursula A; Shapiro, Geoffrey I.
Afiliación
  • Konstantinopoulos PA; Dana-Farber Cancer Institute, Boston, MA, USA. panagiotis_konstantinopoulos@dfci.harvard.edu.
  • Cheng SC; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Supko JG; Massachusetts General Hospital, Boston, MA, USA.
  • Polak M; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Wahner-Hendrickson AE; Mayo Clinic, Rochester, MN, USA.
  • Ivy SP; National Cancer Institute, Bethesda, MD, USA.
  • Bowes B; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Sawyer H; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Basada P; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Hayes M; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Curtis J; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Horowitz N; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Wright AA; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Campos SM; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Ivanova EV; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Paweletz CP; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Palakurthi S; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Liu JF; Dana-Farber Cancer Institute, Boston, MA, USA.
  • D'Andrea AD; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Gokhale PC; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Chowdhury D; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Matulonis UA; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Shapiro GI; Dana-Farber Cancer Institute, Boston, MA, USA.
Br J Cancer ; 126(7): 1027-1036, 2022 04.
Article en En | MEDLINE | ID: mdl-34887522
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Antineoplásicos Límite: Humans Idioma: En Revista: Br J Cancer Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Antineoplásicos Límite: Humans Idioma: En Revista: Br J Cancer Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos